Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
Intended to explore synthetic lethality and develop better combinatorial regimens, we screened colorectal cancer (CRC) cells using poly ADP-ribose (PAR) polymerase (PARP) inhibitors and cytotoxic agents. We studied four PARP inhibitors and three DNA-damaging agents, and their combinations using sulforhodamine B assay. Rucaparib demonstrated the greatest synergy with irinotecan, followed by olaparib and PJ34. Rucaparib and irinotecan was further subjected to detailed examination to determine combination index (CI) and underlying mechanism of action. Effectiveness and sequence dependence of this combination were assessed in microsatellite stable (MSS) and unstable (MSI) CRC and HCT116 isogenic cell lines. The degree of cell cycle arrest and apoptosis was determined by FACS. In vivo studies were performed to confirm efficacy of this combination. PAR levels in MSI and PARP expression in MSI and MSS cell lines were diminished upon combinatorial treatment. HCT116 isogenic cells revealed the importance of p21, p53 and PTEN in exerting synergy. In MSI cells, administration of rucaparib prior to irinotecan enhanced cytotoxicity compared to other strategies explored. FACS revealed S-phase arrest and increased late-stage apoptosis in MSS, and G2-M arrest and total and early-stage apoptosis in MSI cells. In in vivo murine xenograft models, a significant reduction in tumor volume and expression of Ki67, pancytokeratin and RPS6KB1, and increase in expression of caspase 3 were observed with the combination. In conclusion, among the various combinations studied, rucaparib plus irinotecan was the most synergistic one. Alterations in cell cycle arrest and apoptosis were dependent on MSI status in CRC cells.
KeywordsPARP Rucaparib Irinotecan Colorectal cancer Combinatorial Synergy
S. Goel is supported by a K-12 award from the National Cancer Institute of the National Institutes of Health 1K12CA132783-01A1, and an Advanced Clinical Research Award (ACRA) in colon cancer, by the ASCO (now Conquer) Cancer Foundation. The authors would like to thank Dr. Tanya Dragic from Department of Microbiology & Immunology, Dr. Balazs Halmos from Department of Medicine and Dr. Thomas J. Ow from Department of Pathology, Albert Einstein College of Medicine/Montefiore Medical Center for their helpful advice on various technical issues examined in this paper, and Dr. Dhanonjoy C. Saha from Office of Grant Support, Albert Einstein College of Medicine, for his advice and comments. The authors also greatly appreciate the expert advice/assistance of Hillary Guzik, Analytical Imaging Facility, Albert Einstein College of Medicine in microscopy/IHC studies. The imaging was conducted in the Analytical Imaging Facility, which is funded by the NCI Cancer Grant P30CA013330.
The work was supported by the K-12 award from the National Cancer Institute of the National Institutes of Health 1K12CA132783-01A1, and an Advanced Clinical Research Award (ACRA) in colon cancer, by the ASCO (now Conquer) Cancer Foundation to Dr. Sanjay Goel.
Compliance with ethical standards
Conflict of interest
Titto Augustine declares that he has no conflict of interest. Radhashree Maitra declares that she has no conflict of interest. Jinghang Zhang declares that she has no conflict of interest. Jay Nayak declares that he has no conflict of interest. Sanjay Goel declares that he has no conflict of interest.
This article does not contain any studies with human participants. All applicable institutional guidelines (by Institutional Animal Care and Use Committee) for the care and use of animals were followed.
- 8.Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G, Oliver FJ (2005) PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386(Pt 1):119–125. https://doi.org/10.1042/BJ20040776 CrossRefGoogle Scholar
- 11.Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y (2014) Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349(3):408–416. https://doi.org/10.1124/jpet.113.210146 CrossRefGoogle Scholar
- 12.Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S (2015) Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 112(2):313–318. https://doi.org/10.1038/bjc.2014.561 CrossRefGoogle Scholar
- 13.Gandhi JS, Goswami M, Sharma A, Tanwar P, Gupta G, Gupta N, Pasricha S, Mehta A, Singh S, Agarwal M, Gupta N (2017) Clinical impact of mismatch repair protein testing on outcome of early staged colorectal carcinomas. J Gastrointest Cancer 49:406–414. https://doi.org/10.1007/s12029-017-9954-5 CrossRefGoogle Scholar
- 15.Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573. https://doi.org/10.1016/j.ccr.2005.05.014 CrossRefGoogle Scholar
- 16.Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953–1961. https://doi.org/10.1158/0008-5472.CAN-07-5659 CrossRefGoogle Scholar
- 17.Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235. https://doi.org/10.1038/73432 CrossRefGoogle Scholar
- 21.Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF, Klinghofer V, Liu X, Olson A, Saltarelli MJ, Shi Y, Stavropoulos JA, Zhu GD, Penning TD, Luo Y, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK (2008) The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 28(5A):2625–2635Google Scholar
- 24.He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, Wang CZ, Du W, Yuan CS, He TC, Zhang BQ (2011) Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ss-catenin signaling. Int J Oncol 38(2):437–445. https://doi.org/10.3892/ijo.2010.858 CrossRefGoogle Scholar
- 25.Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, Cheng RH, Wang L, Lam KS (2009) A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30(30):6006–6016. https://doi.org/10.1016/j.biomaterials.2009.07.015 CrossRefGoogle Scholar
- 28.Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD (2013) Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 8(3):e58089. https://doi.org/10.1371/journal.pone.0058089 CrossRefGoogle Scholar
- 29.Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 33(5):2135–2142. https://doi.org/10.3892/or.2015.3876 Google Scholar
- 35.Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlstrom A, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9(3):829–841. https://doi.org/10.1016/j.celrep.2014.09.028 CrossRefGoogle Scholar
- 40.Marechal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5(9). https://doi.org/10.1101/cshperspect.a012716
- 42.Williams AB, Schumacher B (2016) p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med 6(5). https://doi.org/10.1101/cshperspect.a026070
- 48.Lee YC, Lee CH, Tsai HP, An HW, Lee CM, Wu JC, Chen CS, Huang SH, Hwang J, Cheng KT, Leiw PL, Chen CL, Lin CM (2015) Targeting of topoisomerase I for prognoses and therapeutics of camptothecin-resistant ovarian cancer. PLoS One 10(7):e0132579. https://doi.org/10.1371/journal.pone.0132579 CrossRefGoogle Scholar
- 50.McIlwain DR, Berger T, Mak TW (2015) Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 7(4). https://doi.org/10.1101/cshperspect.a026716
- 53.Al-Ali H, Ding Y, Slepak T, Wu W, Sun Y, Martinez Y, Xu XM, Lemmon VP, Bixby JL (2017) The mTOR substrate S6 kinase 1 (S6K1) is a negative regulator of axon regeneration and a potential drug target for central nervous system injury. J Neurosci 37(30):7079–7095. https://doi.org/10.1523/JNEUROSCI.0931-17.2017 CrossRefGoogle Scholar
- 54.Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M (2014) The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 53(7):852–864. https://doi.org/10.3109/0284186X.2014.895036 CrossRefGoogle Scholar
- 55.Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S (2015) Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899–906. https://doi.org/10.1158/1078-0432.CCR-14-0894 CrossRefGoogle Scholar